Navigation Links
Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies
Date:11/1/2007

in survival over time. "We wanted to understand if the new therapies available to these patients would translate directly into improved survival," said lead author Shaji Kumar, MD, of the Mayo Clinic.

The first analysis studied 387 patient records to compare disease relapses before and after December 31, 2000, based on the availability of thalidomide and subsequent clinical trials of bortezomib and lenalidomide. The second analysis was conducted over a 36-year period (1971-2006) with a larger group of 2,981 patients with newly diagnosed MM. These patients were divided by date of diagnosis (before or after January 1, 1997) to understand the significance of the novel advances in MM therapies.

Study results illustrated a dramatic improvement in survival among patients diagnosed in recent years, both from the time of diagnosis and from relapse after stem cell transplantation. Among the patients in the relapse group, the researchers noted a significant improvement in overall survival for patients relapsing after 2000, compared with those relapsing before 2000 (24 vs. 12 months). Patients relapsing before 2000 were less likely to receive a prompt transplant and more likely to have relapsed disease at the time of transplant and to have had more treatment regimens prior to transplant, compared with the group who relapsed after 2000, but the improvement seen in the recent times was independent of these differences.

In the larger group of newly diagnosed MM patients, diagnosis within the last decade translated into a 50 percent improvement in overall survival (45 vs. 30 months). Though the team divided the groups into six-year intervals to understand trends throughout the 36 years, they found no significant changes in survival until the most recent six-year period. When the team examined the relative impact of age and gender, they found that patients younger than 65 benefited the most from the recent improvements and that female patients fared slightly be
'/>"/>

SOURCE American Society of Hematology
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
4. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
5. Insmed Inc. Welcomes Studies Linking IGFBP-3 to Prevention of Blindness in Premature Infants
6. Resveratrol Studies Suggest Broad Implications for SIRT1 Activation in Neurodegenerative Diseases of Aging Such as Alzheimers Disease
7. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
8. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
9. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
10. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
11. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Pa. , Aug. 3, 2015 VWR ... laboratory products, services and solutions, announces the redesign of its ... customers. When visiting the new site, guests ... with bold colors and vivid images.  Each country site now ... an A to Z product menu; and , the ...
(Date:8/3/2015)... SPRINGS, Florida , August 3, 2015 /PRNewswire/ ... HOLD -- FN Media Group LLC, PIV757417 The ... Focus on Developing Orphan Drug Products & Treatments ... now OFF HOLD. Distribution time: 3 Aug 2015 ... agreements between biotech companies, military surgical research and ...
(Date:8/3/2015)... 2015  Charleston Laboratories, Inc., an emerging specialty ... development program with a Phase 1 study on ... CL-H1T contains fast-dissolving promethazine and sumatriptan.  This novel ... for migraine headache pain and migraine-induced nausea and ... migraine headaches also suffer from nausea and vomiting," ...
Breaking Medicine Technology:VWR's New Website Redesign Provides Improved Functionality for Customers 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6Charleston Laboratories, Inc. Initiates Patient Enrollment in a Phase 1 Study of Charleston's Second Product, CL-H1T 2
... , AUSTIN, Texas, Dec. 9 Ascension ... recent hiring of two veteran executives, L. Robert Johnston, Jr. ... Vice President of Marketing. "These individuals bring a wealth of ... future growth of Ascension," said Guy Mayer, CEO. "As members ...
... Dec. 9 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX ) ... to the Company,s Board of Directors. Dr. Sanders brings ... physician and professor of medicine. , "We are ... said Zola P. Horovitz, Ph.D., Chairman of the Board of ...
Cached Medicine Technology:Ascension Orthopedics Hires Key Senior Executives 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 2BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 3BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors 4
(Date:8/3/2015)... ... ... an opinion piece published July 28 by the Washington Post, the conventional wisdom ... may not be accurate. While this system may work for some people, the author notes ... both on the individual and at what point that person is in their weight loss ...
(Date:8/3/2015)... ... August 03, 2015 , ... BESLER Consulting today ... B2B Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, ... for the launch of their Readmissions Analytics product was selected as one of ...
(Date:8/3/2015)... ... August 03, 2015 , ... A ... while an overwhelming number of Hispanics believe people can positively affect their diabetes, ... of participants queried said making diet changes was important. Far fewer participants mentioned ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact ... AUGUST 3, 2015 – Since winning a South by Southwest® (SXSW®) Interactive Innovation ... an organization whose mission is to develop technology for the sake of humanity ...
(Date:8/3/2015)... ... August 03, 2015 , ... AxoGen, Inc. (NASDAQ: AXGN), a leader ... present at the Wedbush Healthcare Conference on Wednesday, August 12, 2015 at 9:45am (ET) ... archived replay of the Company’s presentation may be accessed via the investor relations section ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... Pediatric rankings include top 30 hospitals in six specialty fields ... ... 30 U.S.News & World Report, one of the,nation,s leading sources of ... Children,s Hospitals,published online at http://www.usnews.com/pediatrics and in the magazine,s,June 9 ...
... Company to evaluate appeal options, TORONTO, May ... PMD; Amex: PME) today announced it has been ... it will not continue to,support PreMD,s plan for ... it intends to delist the Company,s common stock ...
... cancer were more likely than whites to die in ... among blacks for life-extending treatment even in the face ... by researchers at Dana-Farber Cancer Institute in Boston. ,The ... meeting of the American Society of Clinical Oncology in ...
... finds , , FRIDAY, May 30 (HealthDay News) -- Cirque ... to those of elite athletes in competitive sports, say ... 2006. , Injuries of the knee and ankle were ... all injuries to the upper extremities. Most injuries (45 ...
... GLENWOOD, Ill., May 30 Landauer, Inc. (NYSE:,LDR) announced ... cash dividend of $0.50 per share for the third ... July 3, 2008, to shareholders of record,on June 13, ... provider of analytical services to determine,occupational and environmental radiation ...
... One of the Easiest Paths to Fitness, INDIANAPOLIS, May ... fitness method, think again: taking a stroll is,an easy way ... according to three researchers who presented findings today at the,55th ... A study of 14 morbidly obese patients was designed to ...
Cached Medicine News:Health News:U.S.News & World Report Debuts First Specialty Rankings of America's Best Children's Hospitals 2Health News:U.S.News & World Report Debuts First Specialty Rankings of America's Best Children's Hospitals 3Health News:Delisting Notification Received from the American Stock Exchange 2Health News:Black patients with terminal cancer more likely to choose aggressive care at end of life 2Health News:Injury Patterns Similar for 'Circus' Artists, Elite Athletes 2Health News:Brisk Walking Lowers Blood Pressure, Increases Fitness in Obese 2
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Medicine Products: